Indeed, numerous ALK inhibitors have been developed for the treatment of metastatic NSCLC and have gained FDA approval for first-line treatment of ALK-positive NSCLC within the last decade [73]. This evidence concerns the gene ALK and non-small cell lung carcinoma.